This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Biontech US Inc., Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, Stichting Het Nederlands Kanker Instituut—antoni Van Leeuwenhoek Ziekenhis. Active years: 2021-2026.
Company Filing History:
2 out of 9 
2 out of 16 
1 out of 1 Years Active: 2021-2026
Title: Renate De Boer: A Pioneer in T Cell Therapy
Introduction: Renate De Boer, an esteemed inventor based in Diemen, Netherlands, has made significant contributions in the field of immunotherapy with a focus on T cell manufacturing. With a patented innovation aimed at enhancing antigen-specific T cell therapies, her work holds promise for treating various cancers and related diseases.
Latest Patents: De Boer's notable patent, titled "T cell manufacturing compositions and methods," addresses the generation of antigen-specific T cells. The innovative methodologies she developed for controlled ex vivo induction or expansion of T cells can lead to highly specific and beneficial T cell therapies. This groundbreaking invention is pivotal for personal antigen-specific T cell therapy, providing hope for patients struggling with cancer and other disorders.
Career Highlights: Throughout her career, Renate De Boer has gained valuable experience working with prominent organizations, including BioNTech US Inc. and the Netherlands Cancer Institute (Antoni van Leeuwenhoek Hospital). Her involvement with these leading institutions underscores her dedication to advancing cancer treatment through innovative approaches in immunotherapy.
Collaborations: Renate has collaborated with distinguished professionals in her field, including Marit M Van Buuren and Divya Reddy Lenkala. These partnerships have contributed to her research and advancements in T cell therapies, highlighting the importance of teamwork in scientific discovery.
Conclusion: Renate De Boer stands out as a notable inventor whose work in T cell manufacturing and therapeutic methods is paving the way for future advancements in cancer treatment. Her patent and collaborative efforts reflect her commitment to improving patient outcomes through innovative therapies. As the field of immunotherapy continues to evolve, De Boer’s contributions will undoubtedly leave a lasting impact.